NCT06090539: An ongoing trial by Bristol-Myers Squibb
This trial is ongoing. It must report results 2 years, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06090539 |
|---|---|
| Title | A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 29, 2023 |
| Completion date | Oct. 28, 2027 |
| Required reporting date | Oct. 27, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 23, 2025 |
| Days late | None |